Kinoxis Therapeutics: Funding, Investors & Team (Sep 2026)
Kinoxis Therapeutics, an emerging biotechnology company located in Australia, is focused on advancing the development of innovative therapeutic compounds for substance use disorders and other conditions affecting the central nervous system. The company has acquired the rights to these compounds from the University of Sydney, with the primary candidate showing promising effects in various animal studies and is currently undergoing preclinical trials.
Kinoxis Therapeutics has raised $9.6M across 1 funding round on record, the most recent a Series B of $9.6M announced in Aug 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kinoxis Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Kinoxis Therapeutics Funding Rounds
Kinoxis Therapeutics Founders and Leadership Team
Contact details for the Kinoxis Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Kinoxis Therapeutics Funding Compared to Other Biotechnology Startups
Kinoxis Therapeutics' latest round of $9.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kinoxis Therapeutics in Biotechnology and Melbourne
Companies Similar to Kinoxis Therapeutics
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Kinoxis Therapeutics Funding FAQs
What does Kinoxis Therapeutics do?
Kinoxis Therapeutics, an emerging biotechnology company located in Australia, is focused on advancing the development of innovative therapeutic compounds for substance use disorders and other conditions affecting the central nervous system. The company has acquired the rights to these compounds from the University of Sydney, with the primary candidate showing promising effects in various animal studies and is currently undergoing preclinical trials.
How much funding has Kinoxis Therapeutics raised?
Kinoxis Therapeutics has raised $9.6M across 1 round on record. The most recent is a Series B of $9.6M announced in Aug 2024.
When did Kinoxis Therapeutics last raise funding?
Kinoxis Therapeutics' most recent funding round on record is a Series B of $9.6M, announced in Aug 2024.
Who founded Kinoxis Therapeutics?
FundedIQ lists Michael Bowen (Founder) at Kinoxis Therapeutics.
Where is Kinoxis Therapeutics headquartered?
Kinoxis Therapeutics is based in Melbourne, Victoria, Australia.
How many employees does Kinoxis Therapeutics have?
Kinoxis Therapeutics is in the 11-50 employee band.
How does Kinoxis Therapeutics' funding compare to other Biotechnology startups?
Kinoxis Therapeutics' latest round of $9.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Kinoxis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kinoxis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.